Clinical Lipidology
Livrare gratis la comenzi peste 500 RON. Pentru celelalte comenzi livrarea este 20 RON.
Disponibilitate: La comanda in aproximativ 4 saptamani
Editura: Elsevier
Limba: Engleza
Nr. pagini: 432
Coperta: Hardcover
Dimensiuni:
An aparitie: 2 Mar. 2023
Description:
|
||
Table Of Contents:
|
||
SECTION I INTRODUCTION/BASIC MECHANISMS 1 Overview of Lipids and Atherosclerosis SECTION II RISK ASSESSMENT 2 Overview of Risk Assessment 3 Measurement of Low- Density Lipoprotein Cholesterol, Non-High- Density Lipoprotein Cholesterol, Apolipoprotein B, and Low- Density Lipoprotein Particle Concentration 4 Triglycerides, Triglyceride- Rich Lipoproteins, and High- Density Lipoprotein in Coronary Heart Disease Risk Assessment 5 Lipoprotein(a) in Cardiovascular Risk Assessment 6 Clinical Evaluation for Genetic Testing and Secondary Causes of Dyslipidemia 7 Polygenic Risk Scores 8 High- Sensitivity C- Reactive Protein 9 Emerging Assays for Risk Assessment 10 Imaging Atherosclerosis for Risk Stratifi cation: Cardiac Computed Tomography and Carotid Ultrasound SECTION III THERAPY 11 Overview of General Approach to Management of Dyslipidemias 12 Treatment Guidelines Overview: American Heart Association/American College of Cardiology/Multisociety Guideline and Updates 13 Treatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines 14 Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 15 Updated Clinical Guide to Exercise and Lipids 16 Obesity, Lipids, and Cardiovascular Disease 17 Statins 18 Cholesterol Absorption Inhibitors 19 Omega- 3 Fatty Acids 20 Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition 21 Inclisiran 22 Bempedoic Acid 23 Pemafi brate: A New Selective Peroxisome Proliferator-Activated Receptor- _ Modulator for Hypertriglyceridemia Management 24 Anti- inflammatory Therapy for Cardiovascular Disease 25 Nutraceuticals and Functional Foods for Cholesterol Reduction SECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS 26 Evolving Therapeutic Targets: Lipoprotein(a) 27 Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias 28 Evolving Therapeutic Targets: Apolipoprotein C- III 29 Evolving Therapeutic Targets: Cholesteryl Ester Transfer Protein Inhibition 30 Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders SECTION V SPECIAL PATIENT POPULATIONS 31 Special Patient Populations: Diabetes and Metabolic Syndrome 32 Special Patient Populations: Women and Older Adults 33 Special Patient Populations: Children and Adolescents 34 Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias 35 Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia 36 Special Patient Populations: Acute Coronary Syndromes 37 Special Patient Populations: Transplant Recipients 38 Special Populations: Chronic Kidney Disease 39 Special Patient Populations: Lipid Abnormalities in High- Risk Racial/Ethnic Groups 40 Persons With Human Immunodeficiency Virus |
An aparitie | 2 Mar. 2023 |
Autor | Christie M. Ballantyne MD FACP FACC |
Editura | Elsevier |
Format | Hardcover |
ISBN | 9780323882866 |
Limba | Engleza |
Nr pag | 432 |
Versiune digitala | DA |
Clientii ebookshop.ro nu au adaugat inca opinii pentru acest produs. Fii primul care adauga o parere, folosind formularul de mai jos.